Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year

You may also be interested in...

South Korea’s Celltrion Optimistic On June EMA Approval For Remicade Biosimilar

Johnson & Johnson may soon face more competition to Remicade from Celltrion’s biosimilar Remsima, with the South Korean company more optimistic about EMA approval following a positive response at one of the world’s largest rheumatology congresses.

Celltrion Files For Korea Approval Of Herceptin Biosimilar

Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.

Korea’s Celltrion Seeks New Trial Design For Rituxan Biosimilar Phase III

Celltrion says it will launch Phase III trials in the second half of 2013 with a new design, after completing a Phase I trial this month.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts